Risultati di ricerca - Portale di modelli di dati medici (MDM-Portal)

Filtra i risultati della ricerca
Seleziona modelli di dati

Modelli di dati selezionati

Devi effettuare il log in per selezionare i modelli di dati da scaricare per successive analisi

378 Risultati di ricerca.

Eligibility Prostatic Neoplasms NCT00537381

- 27/09/21 - 1 modulo, 1 ItemGroup, 10 elementi, 1 linguaggio

ItemGroup: Inclusion Criteria

An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00537381

Eligibility Prostate Cancer NCT01009736

- 27/09/21 - 1 modulo, 1 ItemGroup, 16 elementi, 1 linguaggio

ItemGroup: Inclusion Criteria

Effects of Tomato-Soy Juice on Biomarkers in Patients With Prostate Cancer Undergoing Prostatectomy; ODM derived from: https://clinicaltrials.gov/show/NCT01009736

Eligibility Prostate Cancer NCT00881725

- 27/09/21 - 1 modulo, 2 itemgroups, 21 elementi, 1 linguaggio

Itemgroups: Inclusion Criteria, Exclusion Criteria

A Study of Pre-operative Metformin in Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00881725

Eligibility Prostate Cancer NCT00716794

- 27/09/21 - 1 modulo, 1 ItemGroup, 16 elementi, 1 linguaggio

ItemGroup: Criteria

A Phase I/II Study of HE3235 in Patients With Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00716794

Effect of GSK958108 on ejaculatory latency time (ELT); NCT00861484 - Logs/Repeats

- 27/09/21 - 1 modulo, 12 itemgroups, 130 elementi, 1 linguaggio

Itemgroups: Date of visit, Assessment Date, Adverse Event; Concomitant Agent; Evaluation, Repeat, Liver, Adverse Event, Non-serious Adverse Event, Serious Adverse Event, Concomitant Agent, Laboratory Procedures, Urinalysis, Vital signs, 12 lead ECG, 12 lead ECG, Abnormality, Repeat, Pharmacokinetic aspect, Blood, Repeat

Study ID: 111155 Clinical Study ID: 111155 Study Title: A double blind, parallel group, placebo controlled study to evaluate the effect of a single oral dose of GSK958108 on ejaculatory latency time (ELT) in male patients suffering from premature ejaculation. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00861484 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: GSK958108 , Placebo Trade Name: N/A Study Indication: Premature Ejaculation

Eligibility Carcinoma, Renal Cell NCT02454478

- 20/09/21 - 1 modulo, 2 itemgroups, 35 elementi, 1 linguaggio

Itemgroups: Inclusion Criteria, Exclusion Criteria

Study of Lenvatinib in Combination With Everolimus in Patients With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC); ODM derived from: https://clinicaltrials.gov/show/NCT02454478

Eligibility Metastatic Castration-Resistant Prostate Cancer NCT02405858

- 20/09/21 - 1 modulo, 2 itemgroups, 10 elementi, 1 linguaggio

Itemgroups: Inclusion Criteria, Exclusion Criteria

A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy; ODM derived from: https://clinicaltrials.gov/show/NCT02405858

Eligibility Carcinoma, Renal Cell NCT01441388

- 20/09/21 - 1 modulo, 2 itemgroups, 10 elementi, 1 linguaggio

Itemgroups: Inclusion Criteria, Exclusion Criteria

A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.; ODM derived from: https://clinicaltrials.gov/show/NCT01441388

Prostatic Surgical Intervention GSK study Prostatic neoplasms NCT00883909

- 20/09/21 - 1 modulo, 3 itemgroups, 11 elementi, 1 linguaggio

Itemgroups: Administrative data, prostate surgery, Prostate surgery

Study ID: 103094 Clinical Study ID: ARI103094 Study Title: ARI103094-Follow-Up Study for REDUCE Study Subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00883909 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: dutasteride Trade Name: Zytefor,Zyfetor,Duagen,Avolve,Avodart,Avidart Study Indication: Neoplasms, Prostate

Local Pathology Results GSK study Prostatic neoplasms NCT00883909

- 20/09/21 - 1 modulo, 2 itemgroups, 12 elementi, 1 linguaggio

Itemgroups: Administrative data, Pathology Results

Study ID: 103094 Clinical Study ID: ARI103094 Study Title: ARI103094-Follow-Up Study for REDUCE Study Subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00883909 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: dutasteride Trade Name: Zytefor,Zyfetor,Duagen,Avolve,Avodart,Avidart Study Indication: Neoplasms, Prostate CRF Seiten: 934-977

Eligibility Neoplasms, Prostate DRKS00009657 NCT00056407 - Eligibility Neoplasms, Prostate NCT00056407

- 20/09/21 - 1 modulo, 2 itemgroups, 12 elementi, 1 linguaggio

Itemgroups: Inclusion Criteria, Exclusion Criteria

"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk; ODM derived from: https://clinicaltrials.gov/show/NCT00056407

Eligibility Prostate Cancer NCT00500110

- 20/09/21 - 1 modulo, 2 itemgroups, 15 elementi, 1 linguaggio

Itemgroups: Inclusion Criteria, Exclusion Criteria

Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00500110

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.